Warfarin Sodium is a premium-grade, high-purity active pharmaceutical ingredient (API), manufactured and supplied as a solid white crystalline powder or as a crystalline clathrate form in a hermetically sealed, industrial-grade 25 kg drum meeting rigorous pharmacopoeial specifications (BP/EP/USP) for professional, industrial-scale usage.
It is a 4-Hydroxycoumarin structural analog with vitamin K antagonism activity. The API acts as a Vitamin K epoxide reductase inhibitor within the liver. By binding to the VKORC1 enzyme subunit, it effectively blocks vitamin K1 epoxide recycling, depleting the functional hydroquinone form of the vitamin. This specific mechanism of action reduces the γ-carboxylation activation of the vitamin K-dependent procoagulant proteins: Factors II, VII, IX, and X, in addition to the endogenous anticoagulants Protein C and Protein S. This competitive interaction results in the hepatic synthesis of biologically inactive coagulation factor precursors, thus producing a potent, predictable, and extended anticoagulation effect.
This API is the sodium salt form of Warfarin base, validated for water solubility. As a generic, off-patent pharmaceutical drug substance, it is the primary active substance in the manufacture of finished dosage forms for large-scale supply. It is used as the active molecular entity in the following applications:
-
Thrombosis Prophylaxis & Therapy: It is a first-line ingredient for FDA/TGA/EMA-compliant oral tablets used for the prevention and treatment of deep vein thrombosis (proximal or established DVT) and acute pulmonary embolism (PE).
-
Secondary Prevention: It is a core component in the manufacturing of drugs to prevent recurrent thromboembolic events in stroke-prone patients, specifically those with non-valvular atrial fibrillation, bioprosthetic heart valves, or a history of venous thromboembolism (VTE) or myocardial infarction (MI).
-
Anticoagulation for Mechanical Valves: An essential pharmaceutical intermediate in drugs prescribed for life-long prophylaxis of clot formation in patients after mechanical prosthetic heart valve replacement.
Sourced from cGMP (Current Good Manufacturing Practices) certified suppliers and manufacturers in China, the product is supplied with complete Certificate of Analysis and is validated to minimize related substances and control the potency of the active clathrate intermediate. It has a chemical formula of C₁₉H₁₅NaO₄ and a molecular weight of 330.31 g/mol. The 25 kg sealed drum provides a safe, bulk economical packaging solution for multinational pharmaceutical corporations, generic medicine compounders, and hospital formularies.
Important Regulatory and Safety Notice: Warfarin Sodium is a designated human prescription active ingredient with a narrow therapeutic index. It is available solely for commercial pharmaceutical intermediate purposes. Procurement of this product is restricted to licensed drug manufacturers, R&D institutions, and commercial entities holding a valid current Drug Manufacturing License or pharmaceutical wholesale authorization. Final usage is subject to applicable and enforced national drug and health regulations regarding the procurement, handling, and formulation of biological anticoagulant substances. Strict adherence to cold chain storage protocols (8°C-25°C) and light-restricted conditions is mandatory for API stability.

















